Sorrento Therapeutics
As of the edition of 20 October 2026, Sorrento Therapeutics runs 12 drugs; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Sorrento Therapeutics was bankrupt.
- Sorrento Therapeutics, Inc.: bankrupt
Drugs by status
| Status | Count |
|---|---|
| Active | 4 |
| Stopped | 5 |
| Status not established | 3 |
| Total | 12 |
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Sorrento Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Lungs and airways: 18 trials led
- Infections: 17 trials led
- Cancer: 8 trials led